LENZ LENZ Therapeutics, Inc. Common Stock
XNAS
3.22
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
LENZ
$3.22
—
Key stats
$3.22
Pre-market
$3.25
+0.93%
- 52-Week Range
- $3.12 – $34.27
- YTD
- -79.88%
- Straddle Price
- $3.55
- P/C Vol Ratio
- 1.53
- Market Cap
- $0.1B
- Open
- $3.20
- Day Range
- $3.15 – $3.37
- Volume
- 943,237
- Prev Close
- $3.19
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.39 |
| Cost of Equity (CAPM) | 12.81% (VRP-adj) |
| WACC | 12.80% |
| Volatility Risk Premium | +328.4pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -57.5% |
| Book / Price | 222.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 91.7% |
| FCF Margin (TTM) | -532.8% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $4.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.59 |
| Bollinger Width / SMA20 | 703.2% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$17.99
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.1× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.0× · 8 peers |
| Peer P/B | $82.20 | 18% | median 11.5× · 10 peers |
| Peer P/S | $4.60 | 18% | median 6.5× · 9 peers |
| Market Anchor (SMA50) | $4.29 | 65% | stability 72% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 152
- List Date
- 2024-03-22
- CIK
- 0001815776
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($0.99) (4 est.)
- Headquarters
- Solana Beach, CA
- Homepage
- https://www.lenz-tx.com
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -9.76% | -1.12% | -5.44% |
| Feb | -- | -13.95% | -17.24% | -15.59% |
| Mar | 37.84% | 19.36% | -33.11% | 8.03% |
| Apr | -24.46% | 9.63% | -3.96% | -6.26% |
| May | -3.29% | 1.11% | -12.39% | -4.86% |
| Jun | 14.66% | 0.51% | -23.66% | -2.83% |
| Jul | 40.36% | -0.93% | -8.54% | 10.30% |
| Aug | -4.96% | 28.94% | 4.30% | 9.43% |
| Sep | 4.49% | 18.68% | -26.58% | -1.14% |
| Oct | 18.25% | -39.41% | -15.04%* | -12.07% |
| Nov | 27.46% | 9.27% | -- | 18.37% |
| Dec | -22.75% | -47.37% | -- | -35.06% |
| Total | 87.38% | -45.45% | -79.08% | -12.38% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.59
SMA 50: $4.29
SMA 200: $8.48
Current: $3.22
EMA 12: $3.44
EMA 26: $3.75
MACD: -0.3041 | Signal: 0.0018
BEARISH
ADX (14): 29.89
TREND
+DI: 13.62
−DI: 31.67
Momentum Oscillators
RSI (14): 32.60
NEUTRAL
Stoch %K: 11.91
Stoch %D: 13.44
Williams %R: -86.11
Volume & Volatility
BB Upper: $4.04
BB Lower: $3.14
NEUTRAL
OBV: -39,890,588
Vol SMA 20: 798,695
Vol ROC: 82.97%
ATR: $0.24
True Range: $0.23
HV 20: 59.7%
HV 30: 57.7%
HV 60: 66.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Positive news sentiment around regulatory approvals and market growth
- Strong technical momentum signals from RSI and MACD
- High volatility, indicating a high-risk environment
Primary Risks:
- Negative news headlines can lead to sharp price declines
- Unusual options activity may indicate underlying market concerns
Investment Thesis:
LENZ is an attractive opportunity for investors seeking high-growth potential. The stock's recent rally has been driven by positive regulatory developments and strong technical momentum. While the company faces significant risks, including negative news headlines, we believe the reward-to-risk ratio is currently favorable.
Recent News Sentiment Impact:
The recent news headlines have generally been positive, with LENZ announcing several partnerships and regulatory approvals. This sentiment has contributed to the stock's upward momentum.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BULLISH, Medium-term (1-3 months): BEARISH, Long-term (3-12 months): NEUTRAL
Support/Resistance Levels:
- Lower Band: $4.20
- Middle Band: $5.02
- Upper Band: $5.84
- SMA 20: $5.02
- SMA 50: $5.26
- SMA 200: $11.29
Momentum Signals:
- RSI (14): 44.32 (neutral)
- MACD: -0.03 / Signal: 0.07 / Histogram: -0.03 (bearish)
Volume Analysis:
- Volume SMA 20: 746052.50
- On-Balance Volume (OBV): -31830189.66
- Volume Rate of Change: 29.50%
News & Sentiment Analysis
Recent Headlines Summary: Positive news sentiment around regulatory approvals and market growth
Sentiment Assessment: POSITIVE (based on recent headlines)
Catalyst Identification:
- Upcoming events: Earnings release, product launches
- Regulatory changes: Potential FDA approvals or rejections
Market Narrative: The positive news headlines have contributed to the stock's upward momentum.
Risk & Volatility Assessment
Risk Level: HIGH
Beta Interpretation: 1.46 (high risk relative to market)
Volatility Regime: CURRENT VOLATILITY IS HIGHER THAN AVERAGE
Options Market Signals:
- IV Rank: 38.9% (Medium)
- Current IV: 258.7%
- Expected Move: $1.30 (37 DTE), 7-DTE: $0.68
- Volume Flow: 152 calls vs 272 puts
- Open Interest: 1,267 calls vs 799 puts
Downside Protection:
- Support levels: Lower Band ($4.20)
- Risk management considerations: Stop-loss levels and position sizing considerations
Market Context & Positioning
Sector Performance: LENZ is outperforming its sector peers
Institutional Activity: Volume patterns suggest institutional interest in the stock
Correlation Analysis: R-squared interpretation suggests a moderate correlation between the stock and market
Relative Valuation: LENZ is trading within its historical range.
Key Levels & Action Items
Critical Price Levels:
- Lower Band: $4.20
- Middle Band: $5.02
- Upper Band: $5.84
Breakout/Breakdown Levels:
- SMA 200: $11.29 (resistance level)
Time-Sensitive Catalysts:
- Earnings release
- Product launches
- Regulatory changes (FDA approvals or rejections)
Risk Management:
- Stop-loss levels: Set stop-loss orders based on the Lower Band ($4.20) and Middle Band ($5.02)
- Position sizing considerations: Adjust position size according to risk tolerance and market volatility
Note that this analysis is objective, referencing specific data points and technical indicators. The report highlights conflicts between technical and news signals, assesses data quality, and provides a risk/reward analysis.
Generated
News
All LENZ news →
Earnings History
8 of 9 under expected move
Avg Expected Move
21.92%
Avg Actual Move
9.56%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-05-08 | After-Close | 31.43% | 4.82% | 0.15x | Within |
| 2024-08-14 | After-Close | 21.49% | 3.83% | 0.18x | Within |
| 2025-05-07 | Pre-Market | 18.83% | 2.12% | 0.11x | Within |
| 2025-07-30 | After-Close | 25.20% | 3.22% | 0.13x | Within |
| 2025-11-05 | Pre-Market | 30.84% | 23.46% | 0.76x | Within |
| 2026-01-07 | After-Close | 12.88% | 6.56% | 0.51x | Within |
| 2026-03-24 | Pre-Market | 25.00% | 17.91% | 0.72x | Within |
| 2026-05-11 | After-Close | 15.77% | 20.82% | 1.32x | Exceeded |
| 2026-08-11 | After-Close | 15.83% | 3.26% | 0.21x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
LENZ Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $3.55
7-DTE Move: $3.55
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 168
Put Volume: 257
P/C Volume: 1.53
BEARISH
Call OI: 153
Put OI: 97
P/C OI: 0.634
Total OI: 250
ATM Options Pricing
ATM Call: $2.45
ATM Put: $1.10
Call %: 76.1%
Put %: 34.2%
Chain Summary
Chain Volume: 2,206
Chain OI: 15,517
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 53rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
53%
vs own history
GEX tilt
-0.12
OI-weighted, today
Vanna tilt
-0.15
δ-sensitivity to IV
Charm tilt
+0.08
δ-decay vs time
? What is this?
· 4 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 183.7% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$3.55Oct 21
Beta Analysis
Risk Metrics
Beta: 1.3516
Alpha: -221.41%
Correlation: 0.2160
R-Squared: 4.7%
Stock Volatility: 79.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own LENZ
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $8.6M | #1689 of 3716 | +73.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.1M | #2888 of 6285 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $525K | #2058 of 4729 | +25.9% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $401K | #2682 of 3138 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
LENZ Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 30,593,624 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$873.58K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $616.85K | 70.61% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $220.95K | 25.29% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $25.56K | 2.93% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $10.22K | 1.17% | 2026-06-30 |
5 filers$1.22M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $617.98K | 50.79% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $327.74K | 26.94% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $191.42K | 15.73% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $46.01K | 3.78% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $33.51K | 2.75% | 2026-06-30 |
LENZ Insider Trading (Form 4)
Latest: 2026-06-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Frederic Guerard | Director | Grant (A) | +22,100 opt | — | EDGAR | |
| 2026-06-15 | James W McCollum | Director | Grant (A) | +22,100 opt | — | EDGAR | |
| 2026-06-15 | Shelley B Thunen | Director | Grant (A) | +22,100 opt | — | EDGAR | |
| 2026-06-15 | Kimberlee C Drapkin | Director | Grant (A) | +22,100 opt | — | EDGAR | |
| 2026-06-15 | Zachary Scheiner | Director | Grant (A) | +22,100 opt | — | EDGAR | |
| 2026-06-15 | Jeffrey P. George | Director | Grant (A) | +22,100 opt | — | EDGAR | |
| 2026-06-15 | RA Capital Nexus Fund II, L.P. | Director | Grant (A) | +110,500 opt | — | EDGAR | |
| 2026-03-30 | Evert B. Schimmelpennink | President, CEO and Secretary | Buy (P) | +28,089 | $8.95 | $251.4K | EDGAR |
| 2026-03-30 | Jeffrey P. George | Director | Buy (P) | +5,592 | $8.92 | $49.9K | EDGAR |
| 2026-03-30 | Daniel R. Chevallard | Chief Financial Officer | Buy (P) | +7,500 | $8.57 | $64.3K | EDGAR |
| 2026-01-06 | Marc Odrich | Chief Medical Officer | Grant (A) | +98,200 RSU | — | EDGAR | |
| 2026-01-06 | Shawn Olsson | Chief Commercial Officer | Grant (A) | +98,200 opt | — | EDGAR | |
| 2026-01-06 | Daniel R. Chevallard | Chief Financial Officer | Grant (A) | +98,200 opt | — | EDGAR | |
| 2026-01-06 | Evert B. Schimmelpennink | President, CEO and Secretary | Grant (A) | +358,100 opt | — | EDGAR | |
| 2025-11-19 | Shawn Olsson | Chief Commercial Officer | Mixed | — | $14.09 | -$240.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
LENZ Insider Holdings
9 insiders · @ $3.22
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Versant Vantage II GP, L.P. | 10%+ Owner | 2,609,437 | $8.40M | -$145.81M | 2 | 2025-07-01 |
| 2 | Versant Venture Capital VI, L.P. | 10%+ Owner | 2,299,292 | $7.40M | -$216.73M | 3 | 2025-08-26 |
| 3 | Versant Venture Capital VII, L.P. | 10%+ Owner | 2,060,248 | $6.63M | -$143.73M | 2 | 2025-09-22 |
| 4 | Versant Vantage II GP-GP, LLC | 10%+ Owner | 1,898,092 | $6.11M | -$93.17M | 1 | 2025-10-02 |
| 5 | James W McCollum | Director | 631,099 | $2.03M | $740.4K | 4 | 2026-06-15 |
| 6 | Evert B. Schimmelpennink | President, CEO and Secretary | 77,289 | $248.9K | $251.4K | 5 | 2026-03-30 |
| 7 | Daniel R. Chevallard | Chief Financial Officer | 12,886 | $41.5K | $164.3K | 5 | 2026-03-30 |
| 8 | Jeffrey P. George | Director | 5,592 | $18.0K | $49.9K | 3 | 2026-06-15 |
| 9 | Shawn Olsson | Chief Commercial Officer | 4,733 | $15.2K | -$261.0K | 5 | 2026-01-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
LENZ Board & Officers
As of SEC filings through Jun 15, 2026Directors 12
- Kimberlee C Drapkin · since Jul 28, 2023
- Evert B. Schimmelpennink · since Mar 21, 2024
- Frederic Guerard · since Mar 21, 2024
- James W McCollum · since Mar 21, 2024
- Jeffrey P. George · since Mar 21, 2024
- Peter Kolchinsky · since Mar 21, 2024
- RA Capital Healthcare Fund LP (entity) · since Mar 21, 2024
- RA Capital Nexus Fund II, L.P. (entity) · since Mar 21, 2024
- Ra Capital Management, L.p. (entity) · since Mar 21, 2024
- Rajeev M. Shah · since Mar 21, 2024
- Shelley B Thunen · since Mar 21, 2024
- Zachary Scheiner · since Mar 21, 2024
Officers 4
- Evert B. Schimmelpennink · President, CEO and Secretary · since Mar 21, 2024
- Daniel R. Chevallard · Chief Financial Officer · since Mar 21, 2024
- Marc Odrich · Chief Medical Officer · since Mar 21, 2024
- Shawn Olsson · Chief Commercial Officer · since Mar 21, 2024
10% owners 4
- Peter Kolchinsky · on file since Mar 2024
- RA Capital Healthcare Fund LP (entity) · on file since Mar 2024
- Ra Capital Management, L.p. (entity) · on file since Mar 2024
- Rajeev M. Shah · on file since Mar 2024
Changes in the last 10 years (67)
| Oct 2, 2025 | Versant Ventures VII GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Ventures VII GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Ventures VI GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Ventures VI GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Venture Capital VII, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Venture Capital VI, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Vantage II, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Vantage II GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 2, 2025 | Versant Vantage II GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2025 | RA Capital Nexus Fund II, L.P. no longer listed as a 10% owner in SEC filings |
| Mar 25, 2024 | Rajeev M. Shah first on file as a 10% owner |
| Mar 25, 2024 | Ra Capital Management, L.p. first on file as a 10% owner |
| Mar 25, 2024 | RA Capital Nexus Fund II, L.P. first on file as a 10% owner |
| Mar 25, 2024 | RA Capital Healthcare Fund LP first on file as a 10% owner |
| Mar 25, 2024 | Peter Kolchinsky first on file as a 10% owner |
| Mar 21, 2024 | Zachary Scheiner became a director |
| Mar 21, 2024 | Versant Ventures VII GP-GP, LLC became a 10% owner |
| Mar 21, 2024 | Versant Ventures VII GP, L.P. became a 10% owner |
| Mar 21, 2024 | Versant Venture Capital VII, L.P. became a 10% owner |
| Mar 21, 2024 | Shelley B Thunen became a director |
| Mar 21, 2024 | Shawn Olsson became Chief Commercial Officer |
| Mar 21, 2024 | Rajeev M. Shah became a director |
| Mar 21, 2024 | Ra Capital Management, L.p. became a director |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. became a director |
| Mar 21, 2024 | RA Capital Healthcare Fund LP became a director |
| Mar 21, 2024 | Peter Kolchinsky became a director |
| Mar 21, 2024 | Marc Odrich became Chief Medical Officer |
| Mar 21, 2024 | Lunate Holding RSC Ltd became a 10% owner |
| Mar 21, 2024 | Jeffrey P. George became a director |
| Mar 21, 2024 | James W McCollum became a director |
| Mar 21, 2024 | Frederic Guerard became a director |
| Mar 21, 2024 | Evert B. Schimmelpennink became a director |
| Mar 21, 2024 | Evert B. Schimmelpennink became President, CEO and Secretary |
| Mar 21, 2024 | Daniel R. Chevallard became Chief Financial Officer |
| Mar 21, 2024 | Chimera Investment LLC became a 10% owner |
| Mar 21, 2024 | Alpha Wave Ventures GP, Ltd became a 10% owner |
| Mar 21, 2024 | Alpha Wave Global, LP became a 10% owner |
| Jul 28, 2023 | Kimberlee C Drapkin became a director |
| Jun 19, 2023 | The company announced the departure of Alethia Young as Chief Financial Officer in an SEC filing |
| Jan 6, 2023 | EcoR1 Capital, LLC became a 10% owner |
| Jun 22, 2022 | Davis Jerel no longer listed as a 10% owner in SEC filings |
| Apr 13, 2022 | Phil Gutry reported in an SEC filing no longer being Chief Business Officer |
| Apr 1, 2022 | Alethia Young became Chief Financial Officer |
| Dec 6, 2021 | The company announced the departure of Katherine V Stultz as Chief Operating Officer in an SEC filing |
| Jun 24, 2021 | Versant Ventures VI GP-GP, LLC became a 10% owner |
| Jun 24, 2021 | Versant Ventures VI GP, L.P. became a 10% owner |
| Jun 24, 2021 | Versant Venture Capital VI, L.P. became a 10% owner |
| Jun 24, 2021 | Versant Vantage II, L.P. became a 10% owner |
| Jun 24, 2021 | Versant Vantage II GP-GP, LLC became a 10% owner |
| Jun 24, 2021 | Versant Vantage II GP, L.P. became a 10% owner |
| Jun 24, 2021 | Srinivas Akkaraju became a 10% owner |
| Jun 24, 2021 | Smital Shah became a director |
| Jun 24, 2021 | Samsara BioCapital, L.P. became a 10% owner |
| Jun 24, 2021 | Rizzuto Carlo became a director |
| Jun 24, 2021 | Phil Gutry became Chief Business Officer |
| Jun 24, 2021 | Perry A Karsen became a director |
| Jun 24, 2021 | Matthew Porteus became a director |
| Jun 24, 2021 | Kristen Hege became a director |
| Jun 24, 2021 | Katherine V Stultz became Chief Operating Officer |
| Jun 24, 2021 | Joshua Lehrer-Graiwer became a director |
| Jun 24, 2021 | Joshua Lehrer-Graiwer became President and CEO |
| Jun 24, 2021 | Joseph Jimenez became a director |
| Jun 24, 2021 | Joanne L. Viney became a director |
| Jun 24, 2021 | Davis Jerel became a director |
| Jun 24, 2021 | Davis Jerel became a 10% owner |
| Jun 24, 2021 | Abraham Bassan became a director |
| Jun 24, 2021 | 436, L.p. became a 10% owner |
Not reported recently (18)
- Chimera Investment LLC · Last reported as a 10% owner in an SEC filing dated Mar 28, 2024
- Lunate Holding RSC Ltd · Last reported as a 10% owner in an SEC filing dated Mar 28, 2024
- Alpha Wave Global, LP · Last reported as a 10% owner in an SEC filing dated Mar 28, 2024
- Alpha Wave Ventures GP, Ltd · Last reported as a 10% owner in an SEC filing dated Mar 28, 2024
- Smital Shah · Last reported as a director in an SEC filing dated Jul 21, 2023
- Joseph Jimenez · Last reported as a director in an SEC filing dated Jul 21, 2023
- Rizzuto Carlo · Last reported as a director in an SEC filing dated Jul 21, 2023
- Matthew Porteus · Last reported as a director in an SEC filing dated Jul 21, 2023
- Abraham Bassan · Last reported as a director in an SEC filing dated Jul 21, 2023
- Davis Jerel · Last reported as a director in an SEC filing dated Jul 21, 2023
- Perry A Karsen · Last reported as a director in an SEC filing dated Jul 21, 2023
- Joanne L. Viney · Last reported as a director in an SEC filing dated Jul 21, 2023
- Kristen Hege · Last reported as a director in an SEC filing dated Jul 21, 2023
- Joshua Lehrer-Graiwer · Last reported as a director in an SEC filing dated Feb 23, 2023
- EcoR1 Capital, LLC · Last reported as a 10% owner in an SEC filing dated Jan 6, 2023
- Samsara BioCapital, L.P. · Last reported as a 10% owner in an SEC filing dated Apr 13, 2022
- Srinivas Akkaraju · Last reported as a 10% owner in an SEC filing dated Apr 13, 2022
- 436, L.p. · Last reported as a 10% owner in an SEC filing dated Jul 1, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
LENZ Proposed Insider Sales (Form 144)
Latest: 2025-11-17
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | SHAWN OLSSON | Officer | 40,000 | $1.02M | 2025-11-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
25 ETFs hold LENZ
25 shown · $9.76M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $3.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $1.7M | $75.1B | 2026-10-20 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $971,954 | — | 2026-09-30 |
| 4 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $809,213 | — | 2026-05-31 |
| 5 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $797,857 | $6.6B | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.01% | $668,551 | $11.0B | 2026-10-20 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $545,838 | $13.7B | 2026-10-20 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $455,393 | — | 2026-09-30 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $220,954 | — | 2026-09-30 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.02% | $201,082 | $1.2B | 2026-10-20 |
| 11 | HAPS Harbor Human Capital Factor US Small Cap ETF | Nport | 0.05% | $86,353 | — | 2026-07-31 |
| 12 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $72,376 | — | 2026-09-30 |
| 13 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $32,187 | — | 2026-10-21 |
| 14 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $18,847 | $20.6B | 2026-10-20 |
| 15 | IBBQ Invesco Nasdaq Biotechnology ETF | Nport | 0.02% | $12,899 | — | 2026-05-31 |
| 16 | WSGE Warren Street Global Equity ETF | Nport | 0.01% | $8,414 | — | 2026-04-30 |
| 17 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.00% | $5,353 | — | 2026-05-31 |
| 18 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $4,712 | — | 2026-09-30 |
| 19 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.00% | $3,887 | — | 2026-10-21 |
| 20 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $3,809 | — | 2026-10-21 |
| 21 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $2,969 | — | 2026-10-21 |
| 22 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $1,922 | — | 2026-10-21 |
| 23 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $622 | $3.1B | 2026-10-20 |
| 24 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $80 | — | 2026-10-21 |
| 25 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $32 | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.08
TTM Revenue
$21.48M
TTM Net Income
$-125.96M
TTM Op. Cash Flow
$-113.91M
Quarterly figures (10 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $5.49M | $-31.92M | $-1.02 | $-38.71M |
| Q1 '26 | 2026-03-31 | $1.90M | $-41.49M | $-1.32 | $-33.58M |
| Q4 '25 | 2025-12-31 | $1.59M | $-35.85M | $-1.20 | $-33.02M |
| Q3 '25 | 2025-09-30 | $12.50M | $-16.70M | $-0.59 | $-8.59M |
| Q2 '25 | 2025-06-30 | $5.00M | $-14.91M | $-0.53 | $-11.51M |
| Q1 '25 | 2025-03-31 | — | $-14.62M | $-0.53 | $-16.05M |
| Q4 '24 | 2024-12-31 | — | $-12.46M | $-0.41 | $-9.08M |
| Q3 '24 | 2024-09-30 | — | $-10.21M | $-0.38 | $-10.58M |
| Q2 '24 | 2024-06-30 | — | $-10.25M | $-0.40 | $-15.79M |
| Q1 '24 | 2024-03-31 | — | $-16.65M | $-3.53 | $-23.94M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.45
P/S
4.59
EV/EBITDA
—
EV/Sales
3.46
ROE
-57.4%
ROA
-53.2%
Div Yield
0.00%
FCF Yield
-115.63%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$98.51M
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
10.56M
SI % of Float
54.19%
Days to Cover
13.78
Short Vol Ratio
60.6%
Free Float
19.49M
Float %
62.0%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14